AMAG Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
AMAG AMAG Pharmaceuticals Inc
HCI Hci Group Inc
PSF Cohen & Steers Select Preferred and Income Fund
PJT PJT Partners Inc
ALK Alaska Air Group Inc
RS Reliance Steel & Aluminum Co
HFWA Heritage Financial Corp
MET MetLife Inc
KALU Kaiser Aluminum Corp
STBA S&T Bancorp Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

AMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Closing Price
$13.67
Day's Change
0.01 (0.07%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.67
Day's Low
13.61
Volume
(Light)
Volume:
723,563

10-day average volume:
1,312,130
723,563

Pfizer could know if COVID-19 vaccine candidate is effective by end of October

6:46 am ET October 16, 2020 (MarketWatch)
Print

Tomi Kilgore

Pfizer on track to apply for EUA in the U.S. for potential vaccine by the second-half of November

Shares of Pfizer Inc. rallied in premarket trading Friday, after the drug maker said it is on track to know whether its potential COVID-19 vaccine is effective by the end of October, and currently expects to apply for Emergency Use Authorization by the second-half of November.

Pfizer(PFE), which is developing its vaccine candidate with Germany-based biotechnology company BioNTech S.E.(BNTX), said before it can apply for the EUA, it will have to prove the vaccine is safe.

To do so, the Food and Drug Administration requires two months of safety data on half of the trial participants following the final dose of the vaccine.

"Based on current trail enrollment and dosing pace, we estimate we will reach this milestone in the third week of November," Chief Executive Albert Bourla wrote in an open letter (https://www.pfizer.com/news/hot-topics/an_open_letter_from_pfizer_chairman_and_ceo_albert_bourla) posted on its website Thursday. He said he wrote the letter to clear up any confusion regarding the development and approval of the vaccine candidate.

Pfizer's stock rose 1.1% in premarket trading, while BioNTech shares surged 2.4%.

Once the vaccine candidate is indicated to be effective and safe, Pfizer said another requirement will be to submit manufacturing data showing the "quality and consistency" of the vaccine that will be produced. The company said it expects to have that manufacturing data ready before the safety milestone is reached.

"So let me be clear, assuming positive data, Pfizer will apply for emergency authorization use in the U.S. soon after the safety milestone is achieved in the third week of November," Bourla wrote. "All the data contained in our U.S. application would be reviewed not only by the FDA's own scientists but also by an external panel of independent experts at a publicly held meeting convened by the agency ."

Pfizer's stock has lost 6.7% year to date through Thursday, while BioNTech shares have nearly tripled (up 166.8%). In comparison, the Dow Jones Industrial Average has slipped 0.2% this year.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

October 16, 2020 06:46 ET (10:46 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.